Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|The Lancet Oncology|2021Cited by 96
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M. Syeda, David Polsky, Georgina V Long et al.|The Lancet Oncology|2025Cited by 28
TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma TumorsGregory Chang, David Polsky, Jennifer Wiggins et al.|Journal of Investigative Dermatology|2020Cited by 22
Validation of Circulating Tumor DNA Assays for Detection of Metastatic MelanomaMahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|Methods in molecular biology|2019Cited by 12
Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using <i>TERT</i> promoter mutation-specific droplet digital PCR assays.Christine Cordova, David Polsky, John G. Golfinos et al.|Journal of Clinical Oncology|2019Cited by 12